TITLE

News Blast

PUB. DATE
May 2006
SOURCE
Bio-IT World;May2006, Vol. 5 Issue 4, p36
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents news briefs on the bioinformatics technology as of May 2006. Agreement entered by Ingenuity Systems with Boehringer Ingelheim to provide global access to Ingenuity Pathways Analysis software; Decision of Infotrieve to join the Partner Program of BEA Systems; Collaboration between InforSense and Matrix Science to integrate their technologies.
ACCESSION #
20914779

 

Related Articles

  • Astex in drug discovery jv. Tyler, Alan // European Chemical News;3/15/2004, Vol. 80 Issue 2091, p23 

    Reports on the partnership between drug discovery company Astex Technology and Boehringer Ingelheim for the discovery of novel drugs for therapeutic indication as of March 15, 2004. Description of Astex's drug discovery approach, Pyramid; Responsibilities of Boehringer under the agreement;...

  • Big pharma speeds up Aids drug growth. Tyler, Alan // European Chemical News;7/19/2004, Vol. 81 Issue 2109, p30 

    States that GlaxoSmithKline and Boehringer Ingelheim will accelerate their joint development of a co-package of their AIDS drug Combivir and Viramune for treating HIV infection in the developing world. Information on the AIDS drugs; Importance of the joint venture of the companies.

  • Building Integrative Biology at Boehringer Ingelheim. RUSSELL, JOHN // Bio-IT World;Jan2009, Vol. 8 Issue 1, p16 

    The article reports on the entry of the German family-owned biopharmaceutical conglomerate Boehringer Ingelheim into integrative biology research at its Ridgefield, Connecticut facility. The effort is being led by David de Graaf as vice president (VP) of biotherapeutics and integrative biology....

  • Can Venastat really give you a leg up?  // Environmental Nutrition;Jun98, Vol. 21 Issue 6, p3 

    Focuses on Venastat, a herbal supplement, from Pharmaton Natural Health Products company. What Venastat is promoted for; Contents of Venastat; Benefits of Venastat; Information on Venastat.

  • Pharmaceutical plant approved in Spain.  // Chemical Week;2/28/1996, Vol. 158 Issue 8, p17 

    Reports on Boehringer Ingelheim Corp.'s plan to build a pharmaceutical plant in Barcelona, Spain.

  • Premium promo. Hewitt, Allison // Pharmaceutical Executive;Feb98, Vol. 18 Issue 2, p100 

    Reports that Boehringer Ingelheim has named Makovsky & Co. agency of record for Flomax (tamsulosin), an alpha-blocker used in the treatment of benign prostate hyperplasia.

  • BI Chemicals expands.  // Chemical Week;10/25/1995, Vol. 157 Issue 15, p33 

    Reports on Boehringer Ingelheim Corp.'s fine chemical division, BI Chemicals' plan to expand its Petersburg, Virginia, specialties actives plant.

  • Pipeline.  // Medical Marketing & Media;Aug2004, Vol. 39 Issue 8, p12 

    Reports developments related to pharmaceutical industry as of August 2004. Partnership of Vertex Pharmaceuticals Inc. with Merck & Co. Inc.; Agreement of GlaxoSmithKline PLC and Boehringer Ingleheim to sign a letter of intent for an accelerated development program for the chronic treatment of...

  • Boehringer Ingelheim Group.  // BioPharm International;Dec2001, Vol. 14 Issue 12, p26 

    Focuses on the corporate capabilities of Boehringer Ingelheim group in Germany. Company operations; Marketing strategies; Company history.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics